A phase I trial of AIC100, a novel CAR T-cell therapy targeting ICAM-1, demonstrated a 50% response rate in anaplastic thyroid cancer patients at higher dose levels, with one complete and one partial response.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.